

# TrendsRx® Generic Launch Alert

## Losartan (Cozaar®) and losartan/hydrochlorothiazide (Hyzaar®)\*

### Therapeutic Class

- Cozaar: Angiotensin II receptor blocker (ARB)
- Hyzaar: ARB plus the thiazide diuretic hydrochlorothiazide (HCTZ)

### United States Industry Brand Sales†

- Cozaar: \$948 Million
- Hyzaar: \$689 Million

### Available Dosage Form and Strengths

- Cozaar: Oral tablet; 25 mg, 50 mg, and 100 mg
- Hyzaar: Oral tablet; 50 mg/12.5 mg, 100 mg/12.5 mg, and 100 mg/25 mg

### Launch Date‡

- April 6, 2010

### Market Insight

- The reference brand Cozaar is indicated for:
  - Treatment of hypertension
  - Reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy
  - Treatment of diabetic nephropathy (urinary albumin:creatinine ratio  $\geq 300$  mg/g) in patients with type 2 diabetes and a history of hypertension
- The reference brand Hyzaar is indicated for:
  - Treatment of hypertension
  - Reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy
- The tablet formulations are AB-rated.
- Multiple manufacturers have received final approval by the FDA to market these products.

## Selected Medications Available in the Class<sup>5</sup>

---

- **ARB - Brands:** Atacand® (candesartan cilexetil, AstraZeneca), Diovan® (valsartan, Novartis), Teveten® (eprosartan mesylate, Abbott Laboratories), **Avapro®** (irbesartan, Bristol-Myers Squibb Company), **Benicar®** (olmesartan medoxomil, Daiichi Sankyo), **Micardis®** (telmisartan, Boehringer Ingelheim Pharmaceuticals, Inc.)
- **ARB/thiazide diuretic - Brands:** Diovan HCT® (valsartan/HCTZ, Novartis), Teveten® HCT (eprosartan mesylate/HCTZ, Abbott Laboratories), **Avalide®** (irbesartan/HCTZ, Bristol-Myers Squibb Company), **Benicar HCT®** (olmesartan medoxomil/HCTZ, Daiichi Sankyo), **Micardis® HCT** (telmisartan/HCTZ, Boehringer Ingelheim Pharmaceuticals, Inc.)

## Anticipated Budget Impact

---

- Average wholesale prices:
  - losartan: \$1.68 to \$3.08 per tablet
  - Cozaar: \$1.87 to \$3.42 per tablet
  - losartan/HCTZ: \$2.50 to \$3.41 per tablet
  - Hyzaar: \$2.78 to \$3.79 per tablet
- CVS Caremark will continue to monitor the long-term budget effects of losartan and losartan/HCTZ's introduction into the pharmaceutical marketplace.

## CVS Caremark Response

---

- CVS Caremark offers publications and Web-based applications to ensure that our clients receive timely information regarding generic medications.
- In addition, many CVS Caremark physician- and plan member-targeted offerings are available to help both clients and plan members realize the significant cost savings that generic medications may offer.
- For more information, call your CVS Caremark account representative.

**CVS Caremark encourages the use of generic medications as first-line therapy wherever appropriate.**

**You can count on CVS Caremark to pursue every opportunity to encourage generics utilization by both physicians and plan members.**

Please Note: This document provides a brief overview of the subject. This review is provided as a reference only and is based in part on information derived from third parties.

\* This information is current as of April 8, 2010. The information presented is subject to change and is represented to the best of our knowledge at the time of this publication.

† Industry sales data from the last 12 months.

‡ A launch date may not reflect the actual availability of this medication. Due to circumstances beyond the control of CVS Caremark, information related to prospective medication launch dates is subject to change without notice. This information should not be solely relied upon for decision-making purposes. This medication is expected to be available in pharmacies within a few days of launch.

§ Medications in bold font are currently on the CVS Caremark Performance Drug List and CVS Caremark Primary/Preferred Drug List.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

### References

- CVS Caremark Generic Contracting Team.
- CVS Caremark Internal Pharmacy Budget Impact, Research and Development.
- Medi-Span® Master Drug Data Base v2.5 (electronic version). Medi-Span. Indianapolis, IN. Available at: <http://www.medispn.com/master-drug-database.aspx>. (Cited April 2010)
- Drugs@FDA. Rockville, MD: Food and Drug Administration, Center for Drug Evaluation and Research. <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/>. Accessed March 2010.
- Facts & Comparisons. Facts & Comparisons Web site. <http://www.factsandcomparisons.com/>. Accessed March 2010.
- Teva Announces Favorable Court Ruling in Generic Hyzaar® and Cozaar® Litigation [press release]. Jerusalem, Israel: Teva Pharmaceutical Industries Ltd.; March 2, 2010; [http://www.tevapharm.com/pr/2010/pr\\_909.asp](http://www.tevapharm.com/pr/2010/pr_909.asp). Accessed March 15, 2010.
- Sandoz Launches Authorized Versions of Cozaar® and Hyzaar® Tablets [press release]. Holzkirchen, Germany: Sandoz International GmbH; April 7, 2010; [http://www.sandoz.com/site/en/media\\_room/press\\_releases\\_news/100408.shtml](http://www.sandoz.com/site/en/media_room/press_releases_news/100408.shtml). Accessed April 8, 2010.